References
- Schon M. P., Boehncke W. H. Psoriasis. N Engl J Med 2005; 352: 1899–912
- Saraceno R., Mannheimer R., Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2007, (in press)
- Kragballe K., Corvari L. An innovation in topical therapy: Insights from international dermatologists. Cutis 2007; 79((s2))39–45
- Norman A. W., Bouillon R., Thomasset M. Vitamin D gene regulation structure function analysis and clinical application. Proceedings of the Eighth Workshop on Vitamin D 1991, Berlin. de Gruyter
- Cather J., Menter A. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3: 159–73
- Guenther L., van de Kerkhof P. C., Snellman E., Kragballe K., Chu A. C., Tegner E., et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double‐blind, vehicle‐controlled clinical trial. Br J Dermatol 2002; 147: 316–23
- Papp K. A., Guenther L., Boyden B., Larsen F. G., Harvima R. J., Guilhou J. J., et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48–54
- Douglas W. S., Poulin Y., Decroix J., Ortonne J. P., Mrowietz U., Gulliver W., et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate and calcipotriol in psoriasis vulgaris. Acta Derm Venerol 2002; 82: 131–5
- Van de Kerkhof P. C. The impact of a two compound product containing calcipotriol and betamethasone dipropionate (Daivobet®/Dovobet®) on the quality of life in patients with psoriasis vulgaris: A randomized controlled trial. Br J Dermatol 2004; 151: 663–8
- Ortonne J. P., Kaufmann R., Lecha M., Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double‐blind trial. Dermatology 2004; 209: 308–13
- Cunliffe W. J., Berth‐Jones J., Claudy A., Fairiss G., Goldin D., Gratton D., et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone valerate in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26((5 Pt 1))736–43
- Kragballe K., Gjertesen B. T., de Hoop D., Karlsmark T., van de Kerkhof P. C., Larko O., et al. Double blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193–6
- Van de Kerkhof P. C., Franssen M., de La Brassine M., Kuipers M. Calcipotriol cream in the morning and ointment in the evening: A novel regimen to improve compliance. J Dermatol Treatment 2001; 12: 75–9
- Duweb G. A., Eldebani S., Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React 2003; 25: 127–30
- Carboni I., de Felice C., Bergamin A., Chimenti S. Topical use of calcitriol 3 µg/g ointment in the treatment of mild‐to‐moderate psoriasis. J Eur Acad Dermatol Venereol 2005; 19 Suppl 3: 11–13
- Fredriksson T., Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44
- Abeni D., Picardi A., Pasquini P., Melchi C. F., Chren M. M. Further evidence of the validity and reliability of the SKINDEX‐29: An Italian study on 2,242 dermatological outpatients. Dermatology 2002; 204: 43–9
- Kragballe K., Austad J., Barnes L., Bibby A., de la Brassinne M., Cambazard F., et al. Efficacy results of a 52‐week, randomised, double‐blind, safety study of a calcipotriol/betamethasone dipropionate two‐compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319–26